Key Highlights

  • Clarity Pharmaceuticals shares advanced 13.29% to AUD 2.855, with the price reaching AUD 2.91.
  • Clarity’s Co-PSMA imaging trial met its primary endpoint, while the registrational AMPLIFY study reached its enrolment target in March 2026.
  • Trading volume reached 2,826,850 shares and market capitalisation stood near AUD 1.07bn.
  • Pivotal imaging data, regulatory submissions, CLARIFY recruitment, response durability in SECuRE, isotope supply and cash expenditure are the main milestones.

Clarity Pharmaceuticals (ASX:CU6) attracted renewed market attention after rising 13.29% to AUD 2.855. The shares moved between AUD 2.57 and AUD 2.91, with 2,826,850 units changing hands. The gain placed a fresh spotlight on the company’s latest clinical, regulatory, commercial or corporate development.

The session move sits alongside a one-year return of -38.07%. That longer record provides useful context: a strong day can mark improving expectations, but it does not by itself establish a durable change in value. Future announcements and execution will determine whether buyers remain engaged.

Company Overview

Clarity Pharmaceuticals develops copper-based radiopharmaceuticals for diagnosing and treating cancer. Its theranostic platform pairs copper-64 imaging with copper-67 therapy.

Latest Company Development

Clarity’s Co-PSMA imaging trial met its primary endpoint, while the registrational AMPLIFY study reached its enrolment target in March 2026. The CLARIFY diagnostic trial continued recruiting and the SECuRE programme assessed copper-67 SAR-bisPSMA therapy. A research-and-development tax refund of approximately AUD 9.8 million in May added non-dilutive funding.

Share Price and Market Snapshot

CU6 closed at AUD 2.855, up 13.29%. It reached AUD 2.91 after trading as low as AUD 2.57, while volume totalled 2,826,850 shares. At the closing price, the company was valued at approximately AUD 1.07bn. The one-year share-price change was -38.07%, showing that the latest rise occurred within a broader trend that may differ materially from the single session.

What Investors May Watch Next

Pivotal imaging data, regulatory submissions, CLARIFY recruitment, response durability in SECuRE, isotope supply and cash expenditure are the main milestones.

The next formal update should help investors judge whether the rally reflects improving fundamentals or short-term positioning. Balance-sheet capacity, delivery against stated milestones and evidence of commercial or clinical progress will remain important alongside the headline catalyst.

Risks

  • The share-price gain may reverse if expectations run ahead of operational progress.
  • Clinical, regulatory, commercial or product-development milestones may be delayed or unsuccessful.
  • Customer adoption, reimbursement or partner execution may develop more slowly than expected.
  • Capital requirements could increase debt or dilute existing shareholders.
  • Liquidity and broader market sentiment may amplify price volatility.